United Therapeutics Stock
United Therapeutics Corporation
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Martine A. Rothblatt
- Employees
- 1,400
- Market cap
- $22.9 B
- IPO
- 17/06/1999
United Therapeutics Corporation is a biotechnology company in the healthcare sector headquartered in Silver Spring, US. The firm is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
United Therapeutics stock: price history
1D
-1.5%
1W
-2.9%
1M
+6.9%
6M
-9.4%
YTD
+9.4%
1Y
+23.2%
2Y
+44.1%
5Y
+185.0%
10Y
+355.8%
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~37% stronger price swings than usual
Ask the agents about United Therapeutics
Analyst assessment of United Therapeutics
PRICE TARGET LOW
US$368.00
CONSENSUS
US$630.33
MEDIAN
US$718.00
PRICE TARGET HIGH
US$735.00
0
STRONG BUY
18
BUY
11
HOLD
1
SELL
0
STRONG SELL
30
TOTAL · Buy
As of: 08/10/2026
United Therapeutics stock metrics
P/E
17.64
P/B
3.55
EV/EBITDA
12.56
RETURN ON EQUITY
5.2%
NET MARGIN
42.5%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
91.4%
FLOAT SHARES
39,212,815
AVG. DAILY VOLUME (30D)
912,362
Insider transactions (SEC)
ROTHBLATT MARTINE A
ROTHBLATT MARTINE A
MAHON PAUL A
MAHON PAUL A
MAHON PAUL A
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about United Therapeutics stock
What does United Therapeutics do?
United Therapeutics Corporation is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Martine A. Rothblatt, the company employs around 1,400 people.
The IPO was on 17/06/1999; the stock trades on NASDAQ under the ticker UTHR.
What do analysts say about United Therapeutics stock?
30 analysts rate the stock, the consensus is Buy (as of 08/10/2026).
The average price target is US$630.33, ranging from US$368.00 to US$735.00, with a median of US$718.00.
This is an external assessment, not a statement by Market Jury.
When does United Therapeutics report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly 37% stronger than usual.
Does United Therapeutics pay a dividend?
No, United Therapeutics currently does not pay a dividend.
Which stocks are comparable to United Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get United Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess United Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.